Mizuho Markets Americas LLC Buys 8,774 Shares of ANI Pharmaceuticals, Inc. $ANIP

Mizuho Markets Americas LLC increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.3% in the first quarter, Holdings Channel.com reports. The firm owned 210,768 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,774 shares during the quarter. Mizuho Markets Americas LLC’s holdings in ANI Pharmaceuticals were worth $16,208,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ANIP. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the first quarter worth about $28,000. KBC Group NV acquired a new stake in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its position in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at approximately $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at approximately $50,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $78.53 on Friday. The stock has a market capitalization of $1.79 billion, a PE ratio of 19.88 and a beta of 0.43. ANI Pharmaceuticals, Inc. has a 1-year low of $62.60 and a 1-year high of $99.50. The firm has a fifty day simple moving average of $81.26 and a 200 day simple moving average of $79.48. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 3,313 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at approximately $15,268,698. This represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares of the company’s stock, valued at $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 85,179 shares of company stock worth $6,722,596 over the last ninety days. Company insiders own 8.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ANIP. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim restated a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Finally, Canaccord Genuity Group assumed coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They issued a “hold” rating and a $91.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $105.00.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.